Hybrids of 3-Hydroxypyridin-4(1H)-ones and Long-Chain 4-Aminoquinolines as Potent Biofilm Inhibitors of Pseudomonas aeruginosa Potentiate Tobramycin and Polymyxin B Activity

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL
Zhi-Ying Miao, Xiao-Yi Zhang, Hao-Zhong Long, Jing Lin, Wei-Min Chen
{"title":"Hybrids of 3-Hydroxypyridin-4(1H)-ones and Long-Chain 4-Aminoquinolines as Potent Biofilm Inhibitors of Pseudomonas aeruginosa Potentiate Tobramycin and Polymyxin B Activity","authors":"Zhi-Ying Miao, Xiao-Yi Zhang, Hao-Zhong Long, Jing Lin, Wei-Min Chen","doi":"10.1021/acs.jmedchem.4c01760","DOIUrl":null,"url":null,"abstract":"The biofilm formation of <i>Pseudomonas aeruginosa</i> involves multiple complex regulatory pathways; thus, blocking a single pathway is unlikely to achieve the desired antibiofilm efficacy. Herein, a series of hybrids of 3-hydroxypyridin-4(1<i>H</i>)-ones and long-chain 4-aminoquinolines were synthesized as biofilm inhibitors against <i>P. aeruginosa</i> based on a multipathway antibiofilm strategy. Comprehensive structure–activity relationship studies identified compound <b>30b</b> as the most valuable antagonist, which significantly inhibited <i>P. aeruginosa</i> biofilm formation (IC<sub>50</sub> = 5.8 μM) and various virulence phenotypes. Mechanistic studies revealed that <b>30b</b> not only targets the three quorum sensing systems but also strongly induces iron deficiency signals in <i>P. aeruginosa</i>. Furthermore, <b>30b</b> demonstrated a favorable <i>in vitro</i> and <i>in vivo</i> safety profile. Moreover, <b>30b</b> specifically enhanced the antibacterial activity of tobramycin and polymyxin B in <i>in vitro</i> and <i>in vivo</i> combination therapy. Overall, these results highlight the potential of <b>30b</b> as a novel anti-infective candidate for treating <i>P. aeruginosa</i> infections.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":6.8000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c01760","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

The biofilm formation of Pseudomonas aeruginosa involves multiple complex regulatory pathways; thus, blocking a single pathway is unlikely to achieve the desired antibiofilm efficacy. Herein, a series of hybrids of 3-hydroxypyridin-4(1H)-ones and long-chain 4-aminoquinolines were synthesized as biofilm inhibitors against P. aeruginosa based on a multipathway antibiofilm strategy. Comprehensive structure–activity relationship studies identified compound 30b as the most valuable antagonist, which significantly inhibited P. aeruginosa biofilm formation (IC50 = 5.8 μM) and various virulence phenotypes. Mechanistic studies revealed that 30b not only targets the three quorum sensing systems but also strongly induces iron deficiency signals in P. aeruginosa. Furthermore, 30b demonstrated a favorable in vitro and in vivo safety profile. Moreover, 30b specifically enhanced the antibacterial activity of tobramycin and polymyxin B in in vitro and in vivo combination therapy. Overall, these results highlight the potential of 30b as a novel anti-infective candidate for treating P. aeruginosa infections.

Abstract Image

3-羟基吡啶-4(1H)-酮与长链 4-氨基喹啉的混合物作为铜绿假单胞菌的强效生物膜抑制剂,可增强妥布霉素和多粘菌素 B 的活性
铜绿假单胞菌生物膜的形成涉及多种复杂的调控途径,因此阻断单一途径不可能达到理想的抗生物膜效果。本文基于多途径抗生物膜策略,合成了一系列 3-羟基吡啶-4(1H)-酮和长链 4-氨基喹啉的混合物,作为铜绿假单胞菌的生物膜抑制剂。综合结构-活性关系研究发现化合物 30b 是最有价值的拮抗剂,它能显著抑制铜绿假单胞菌生物膜的形成(IC50 = 5.8 μM)和各种毒力表型。机理研究表明,30b 不仅针对三种法定量传感系统,还能强烈诱导铜绿假单胞菌体内的缺铁信号。此外,30b 还具有良好的体外和体内安全性。此外,在体外和体内联合疗法中,30b 还能特异性地增强妥布霉素和多粘菌素 B 的抗菌活性。总之,这些结果凸显了 30b 作为治疗铜绿假单胞菌感染的新型抗感染候选药物的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信